ABSTRACT
Whole genome sequencing (WGS) allows exploration of the complete compendium of oncogenic processes generating characteristic patterns of mutations. Mutational signatures provide clues to tumour aetiology and highlight potentially targetable pathway defects. Here, alongside single base substitution (SBS), double base substitution (DBS), small insertions and deletions (ID) and copy number aberration (CN) signatures covered by the Catalogue of Somatic Mutations in Cancer (COSMIC) we report signatures from an additional mutation type, structural variations (SV), all extracted de-novo from WGS in 10,983 patients across 16 tumour types recruited to the 100,000 genomes project. Across the five mutation classes we report 137 signatures, with 29 signatures new to COSMIC, including the first COSMIC SV signature reference set. We relate the signatures to clinical outcomes and likely response to therapy, demonstrating the role of signature analysis in delivering the vision of precision oncology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. R.S.H. acknowledges support from the Wellcome Trust (214388) and Cancer Research UK (C1298/A8362). A.S. and J.J. are in receipt of a National Institute for Health Research (NIHR) Academic Clinical Lectureships, funding from the Royal Marsden Biomedical Research Centre, a starter grant for clinical lecturers from the Academy of Medical Sciences. D.N.C. and A.F. are funded by the Oxford NIHR Comprehensive Biomedical Research Centre (BRC). D.C.W. is funded by the NIHR Manchester Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The 100,000 Genomes Project - genomicsengland.co.uk/initiatives/100000-genomes-project. Genomics England has approval from the HRA Committee East of England - Cambridge South (REC Ref 14/EE/1112).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
All data produced are contained in the supplementary tables. Any data which could not be provided in the tables is available through the Genomics England research environment.